Skip to content

Evaluation of the efficacy and safety of topical application of polyherbal unani formulation in the management of Melasma

Evaluation of the efficacy and safety of topical application of Tukhm-e-Turb and Tukhm-e-Jarjir in the management of Kalf (Melasma) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/063053
Enrollment
44
Registered
2024-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80-L99- Other disorders of the skin and subcutaneous tissue

Interventions

Intervention1: ?il??(liniment) which consists of fine powder of Tukme Turb (seeds of Raphanus sativus) and Tukhme Jarjir (seeds of Eruca sativa Miller): A topical Unani formulation ?il??(liniment) whi

Sponsors

Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Clinically diagnosed patients of Kalf (Melasma) by wood’s lamp examination. 2 Patients with Fitzpatrick skin types III, IV and V 3 Patients of all sexes. 4 Patients who are willing to sign the written consent form prior to participation in the study.

Exclusion criteria

Exclusion criteria: 1 Pregnant and lactating women. 2 Patients having used any cosmetic depigmenting agent within 2 weeks prior to inclusion in the study. 3 Female on oral contraceptives and hormone therapy at the time of study. 4 Patients having used topical or systemic corticosteroid within 1 month prior to inclusion in the study. 5 Patients having history of laser treatment or dermabrasion or deep facial peels within the past 3 months. 6 Patients who have a known history or clinically relevant allergy, to any study medication components. 7 Patients who have a known history of renal insufficiency, severe liver or heart diseases, neurological disorders, malignancy, HIV infection, AIDS, etc. 8 Patients unlikely to comply with the study protocol.

Design outcomes

Primary

MeasureTime frame
• modified Melasma Area Severity Index (mMASI) • Patient Global Assessment (PtGA)Timepoint: Baseline,2nd week, 4th week and 6th week

Secondary

MeasureTime frame
Melasma quality of life scale (MELASQoL)Timepoint: Baseline and 6th week

Countries

India

Contacts

Public ContactFaiza Hussain

Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital

mohdanzar878@gmail.com7879552440

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026